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Available online 25 May 2016Background:Multiple myeloma (MM) and its precursor, monoclonal gammopathy of undetermined signiﬁcance
(MGUS), have been linked with several autoimmune conditions in the medical literature. Yet, signiﬁcance of
these associations is not well understood.
Methods: Herein, we provide a comprehensive literature review on autoimmune disorders identiﬁed in patients
with MM and MGUS. Most relevant papers were identiﬁed via searching the PubMed/Medline and EMBASE
databases for articles published from inception until May 1, 2016.
Findings: Scientiﬁc literature on autoimmune conditions in patients with MM and MGUS consists of several case
series and a multitude of case reports. Our analysis suggests an increased prevalence of autoimmune conditions
in patients with MM and monoclonal gammopathy of undetermined signiﬁcance (MGUS), including various
autoimmune hematologic and rheumatologic conditions among other entities. Conversely, persons with various
autoimmune conditions tend to have a higher prevalence of MGUS and MM than the general population.
Conclusions: Future research is required to explore further the link between MGUS/MM and autoimmune
disorders. Inﬂammation in the setting of autoimmunity may serve as a trigger for MGUS and MM. In addition,
a common genetic susceptibility for developing both an autoimmune disease and MM/MGUS might also exist.
Autoimmune hematologic and rheumatologic diseases may pose important clinical problems for the MM
patients. Therefore, a catalogue of these problems is important so that physicians are able to consider, identify
and address them promptly.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Multiple myeloma (MM) is a clonal malignancy of plasma cells
characterized by anoverproduction ofmonoclonal antibodies. Clinically,
this entity is characterized by skeletal lesions, anemia, hypercalcemia
and renal failure. According to the United States Surveillance, Epidemi-
ology and End Results (SEER), the incidence of MM is 6.1/100,000 peo-
ple per year and increases to 30.4/100,000 people per year in those older
than 65 years. Themedian age of diagnosis of MM is 71 years in whites,
and 67 years in blacks [1]. As a rule, monoclonal gammopathy of unde-
termined signiﬁcance (MGUS) precedes MM and carries an average 1%
annual risk of progression to MM or other lymphoproliferative disorder
[2]. While the etiology of both MGUS and MM remains unknown, risk
factors such as advanced age, family history, male gender and environ-
mental factors have been present in both conditions [3].
Several studies link MM with autoimmune disorders; however, the
data has not yet been fully analyzed or systematized. Herein, we review
comprehensively autoimmune conditions that have been associated
with MM and MGUS in the medical literature.
2. Materials and methods
We performed a systematic search on PUBMED/MEDLINE, EMBASE
and foreign articles published from inception to May 1, 2016. We
searched for papers using the following keywords: ‘multiple myeloma’
and ‘monoclonal gammopathy of undetermined signiﬁcance’ with
each of the following keywords: ‘autoimmune’, ‘autoimmunity’, ‘auto-
immune hemolytic anemia’, ‘immune thrombocytopenia’, ‘vasculitis’,
‘polyarthritis’, ‘rheumatoid arthritis’, ‘rheumatologic disease’, ‘nephrotic
syndrome’, ‘autoimmune neutropenia’, ‘thrombocytopenia’, ‘pure red
cell aplasia’, ‘systemic lupus erythematosus’, ‘Sjogren's syndrome’,
‘myasthenia gravis’, ‘multiple sclerosis’ and ‘inﬂammatory bowel
disease’. Several articleswere also obtained via cross-reference checking
and “snowball” method, when databases different from PUBMED and
MEDLINE were accessed.
3. Overview and pathophysiology of autoimmunity and multiple
myeloma
Immune dysregulation plays a key role in lymphomagenesis. Of
note, chronic autoimmune inﬂammatory conditionshavebeen associated
with lymphoproliferative disorders such as lymphoma and chronic
lymphocytic leukemia [4–5].
Indeed, chronic inﬂammation plays an important role in the devel-
opment of lymphoproliferative diseases and other cancers [6]. In fact,
there is current interest in development of targeted therapies that aim
to control inﬂammation, such as with the toll-like receptor (TLR) path-
way. For survival, B-cells in multiple myeloma depend on inﬂammation
pathways involving interleukin (IL)-6, IL-13, and Tumor Necrosis Factor
(TNF)-α. Furthermore, TLR and TLR-ligands expressed by B lympho-
cytes promote their proliferation and survival [7]. Other important
components that help maintaining a favorable microenvironment formalignant B-cells in MM include the B-cell activating factor (BAFF)
which participates in the activation of the nuclear factor κ-B (NF-κB),
an important B-cell malignancy pathway [8].
In recent years, a number of reports and case studies have hinted at
the association between plasma cell dyscrasias and autoimmune disor-
ders [9]. Osserman and Takatsukiwere theﬁrst ones to hypothesize that
chronic antigen stimulationmay trigger the development of plasma cell
dyscrasias [10]. As a result, chronic immune stimulationmay lead to the
development of hematological malignancies by randomly introducing
pro-oncogenic mutations in rapidly dividing cells, including plasma
cells [11].4. Autoimmune hematologic conditions in multiple myeloma
Anemia is almost invariably present patients with MM, either at
diagnosis or as the disease progresses. The pathogenesis of anemia in
MM is usually multifactorial, including a component anemia of
inﬂammation due to myeloma itself, bone marrow replacement with
malignant plasma cells and anemia of renal failure due to erythropoietin
deﬁcit. However, such entities as pernicious anemia, autoimmune
hemolytic anemia and pure red cell aplasia have also been described
in these patients (Table 1).
Thrombocytopenia occurs frequently in patients with plasma cell
dyscrasias. The pathogenesis usually involves marrow replacement by
themyeloma cells or treatmentwith anti-myelomaagents. Neutropenia
in MM is often due to the use of traditional chemotherapy agents,
immunomodulating agents and, less frequently, other agents. Notwith-
standing, there are cases of immune thrombocytopenia and autoim-
mune neutropenia in MM patients described in the literature (Table 1).4.1. Pernicious anemia
Pernicious anemia is characterized by an autoimmune destruction of
gastric parietal cells and antibody-mediated inactivation of the intrinsic
factor resulting inmalabsorption of cobalamin (vitamin B12), thus lead-
ing tomegaloblastic anemia. Some studies established that incidence of
cobalamin deﬁciency in patients with IgAmultiple myeloma andMGUS
is approximately 13.6% (Table 1) [12]. Several publications, including
meta-analysis studies, suggest that pernicious anemia may represent a
risk factor for MM [9,13–14]. In addition, a recent case-control study
found a 1.47 times increase in risk of developing MM in patients with
pernicious anemia [13].While the exact steps of pathogenesis of plasma
cell dyscrasias in patients with pernicious anemia is not well described,
several hypotheses exist. One of them favors occurrence of immune
alterations and chromosome abnormalities in the bone marrow of
patients with pernicious anemia [15]. Another one postulates that
cobalamin deﬁciency may promote carcinogenesis and development
of plasma cell dyscrasias by causing abnormal DNA methylation [16].
Indeed, aberrant DNA methylation patterns have been demonstrated
in patients with MM [17].
Table 1
Hematologic autoimmune disorders associated with multiple myeloma and MGUS in the literature.
Disease Proposed mechanism Epidemiology Therapy References
Pernicious anemia Disruption of B12-mediated methylation Increased prevalence of IgA
MM/MGUS in these patients
Vitamin B12 therapy has not been proven to impact
the multiple myeloma outcome
[9,12–17]
AIHA Occurrence of auto-reactive B-cell clones Prevalence 4–10% Improves after MM therapy [18–22,88]
PRCA Marrow precursor suppression by monoclonal
antibody or paraprotein
Unknown Refractory to immunosuppression; improves with
MM therapy
[23–25]
ITP Clonal autoantibody production Unknown May improve with MM therapy [27,28]
Evans' syndrome Associated with MM and IgA monoclonal
gammopathy
Unknown May improve with MM therapy [29–31]
AIN Clonal expansion of light chain-restricted
anti-neutrophil antibodies
Can be induced by MM therapy (e.g. lenalidomide, etc.)
Rare No change [33–35]
AIHA: autoimmune hemolytic anemia. AIN: autoimmune neutropenia. ITP: immune thrombocytopenia. MM: multiple myeloma. PRCA: pure red cell aplasia, MGUS: Monoclonal
gammopathy of undetermined signiﬁcance.
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Autoimmune hemolytic anemia (AIHA) is known to be associated
with B-cell lymphoproliferative neoplasms. Some studies claim that
4% of patients MM also have AIHA [6,18], while others suggest that
AIHA is only rarely associated with MM [19]. However, a more recent
case series reported that 7 of the 66 (10.6%)MMcaseswere complicated
by AIHA and carried red cell autoantibodies in their serum [20]. In addi-
tion, another 10 cases of AIHA associated with MM have been recently
reported in literature [21]. Of those, seven patients had IgG myeloma
and four - IgAmyeloma [20–21]. Interestingly, one patient in this series
had a biclonal (IgG2 and IgA) MM. With the exception of two patients
with relapsed myeloma, all patients demonstrated remission of AIHA
after therapy for myeloma [20–21]. While the pathogenesis of AIHA
in MM is unclear, it has been hypothesized that signiﬁcant immune
disturbances may allow the development of clones that produce auto-
antibodies against erythrocyte surface antigens [22].4.3. Pure red cell aplasia
Pure red cell aplasia (PRCA) is an acquired autoimmune condition
[23]. PRCA in patients with MM has traditionally been considered a
rare occurrence. Recently, three case reports have described a PRCA
associated with MM [24–26]. In all cases, the diagnosis of PRCA was
made concurrently with the diagnosis of MM. Sarathy et al. described
a patient with PRCA refractory to immunosuppressive therapy that
improved only after the patient was treated with bortezomib [26].
This ﬁnding suggested that PRCA was secondary to MM.4.4. Immune thrombocytopenia
Immune thrombocytopenia (ITP) has been reported in patients with
lymphoproliferative disorders such as chronic lymphocytic leukemia
and non-Hodgkin's lymphoma (NHL). While uncommon, ITP is also
described in patients with MM [27–28]. In a series of six patients,
thrombocytopenia was the initial presentation in two, with myeloma
being diagnosed at a later stage [27–28]. Although the pathogenesis of
ITP in lymphoproliferative disorders is poorly understood, it has been
proposed that intrinsic immune alterations promote generation of
speciﬁc autoreactive platelet antibodies [27]. In addition, ITP can be
associated with AIHA as Evans' syndrome, with hemolysis usually
preceding thrombocytopenia [29]. Two cases of Evans' syndrome have
been described in patients with MM/MGUS [30–31]. However, one of
the cases occurred in a patient with extramedullary plasmacytoma, a
relatively rare plasma cell tumor not uncommonly preceding MM. The
patient had IgA monoclonal gammopathy in serum and urine which
was consistent with the diagnosis of MM [30]. The diagnosis of Evans'
syndrome in this case preceded the diagnosis of MM by four years.Interestingly, the second case of Evans' syndrome was also described
in a patient with IgA MGUS [31].
4.5. Autoimmune neutropenia
Therapy forMMcan result in neutropenia. For instance, lenalidomide-
induced neutropenia occurs in up to 35% of patients [32]. Autoimmune
neutropenia (AIN), characterized by the presence of autoantibodies
directed against neutrophils and an absolute neutrophil count of less
than 1500 cells/μL, rarely occurs secondary to myeloma itself [33].
Aryal et al. [34] have recently reported a rare case of AIN associated
with MM [34]. The authors hypothesized that the cross talk between
T- and B-cells in MM can induce a clonal T-cell expansion and T-cell
receptor gene rearrangement leading to the development of AIN.
Shastri et al. [35] identiﬁed the presence of a clonal expansion of
lymphoid cells that led to light chain-restricted neutrophil-binding
autoantibodies in patients with antibody-induced neutropenia.
5. Rheumatologic disorders in multiple myeloma
Increased prevalence of several rheumatologic conditions has been
linked with multiple myeloma and MGUS (Table 2).
5.1. Rheumatoid arthritis
Rheumatoid arthritis (RA), systemic scleroderma, Sjogren's
syndrome (SS) and systemic lupus erythematosus (SLE) have all been
linked to MM and plasma cell dyscrasias (Table 2) [6,36–37]. Nonethe-
less, the association between MM and RA is rather weak according to
several cohort studies and case reports [9,36–37]. Two recent meta-
analyses did not ﬁnd a statistically signiﬁcant increase in the risk for
MM in patients with RA [9,13]. However, both studies showed a high
level of between-study heterogeneity (I2 N 50%) that could have affected
their conclusions. A subgroup analysis of the study by Shen et al. [13]
revealed that patients with RA are more likely to be diagnosed with
subsequent MM (relative risk [RR] = 1.32). McShane et al. [9] found
an increased risk of MM in patients with RA (RR = 1.18) as well,
although they were not able to show statistical signiﬁcance. In addition,
several case-control studies found that there was an increased risk of
developingMMafter being diagnosedwith RA [38–40]. The discrepancy
between the studies could be due to reverse causality bias. Indeed, RA
preceded the development of MM in case studies andmost case reports
in the literature [37–38]. Consequently, it is conceivable that prolonged
antigenic stimulation present in RA could lead to the development of
MM.
5.2. Systemic lupus erythematosus
The association between SLE and lymphoproliferative disorders is
well known. In a cohort study, nearly 11% of patients with MM were
Table 2
Rheumatologic autoimmune disorders associated with multiple myeloma in the literature.
Disease Proposed mechanism Epidemiology Therapy References
RA RA usually precedes MM; prolonged antigenic stimulation induced
by RA can lead to MM.
Conﬂicting data No change [37–40]
SLE Similar to RA In addition, defective immune surveillance in SLE may
lead to uncontrolled clonal proliferation of plasma cells.
MM tends to be diagnosed at an earlier age. No change [41–43]
DM and PM Chronic immune stimulation leading to B-cell clonal expansion 2.29 relative risk of developing plasma cell
dyscrasias
No change [45–49]
SS IgG myeloma is the most common subtype. SS symptoms may improve
with MM therapy
[13,53–60]
AS Unknown Unknown No change [46,61–66]
LCV Overexpression of IL-6 genes in MM may lead to development of
LCV.
IgG myeloma is more prevalent than other
subtypes.
No change [67–73]
DM: dermatomyositis. HM: hematologic malignancy. IL-6: interleukin-6. MM: multiple myeloma. PM: polymyositis. RA: rheumatoid arthritis. SLE: systemic lupus erythematosus. SS:
Sjogren's syndrome. AS: ankylosing spondylitis. LCV: leukocytoclastic vasculitis.
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increased prevalence of SLE in family members of patients with MM
has also been reported [42]. Review of literature revealed more than a
dozen cases of MM in patients with SLE [43]. In all of them, SLE either
preceded or was diagnosed concurrently with MM. The median age of
diagnosis of MM in patients with SLE was 45 years, which is younger
than the median age of 64 years seen in the general population [44].
The pathophysiology underlying the association between SLE and MM
is unclear. Similar to RA, it is plausible that prolonged antigenic stimula-
tion present in SLE leads to development of MM. Conversely, defective
immune surveillance in SLE may lead to selection of speciﬁc B-cell
clones, thus leading to the development of MM.5.3. Dermatomyositis and polymyositis
Dermatomyositis (DM) and polymyositis (PM) are associated with
hematologic malignancies [45]. A recent retrospective cohort study of
4641 patients with MM/MGUS found that DM and PM are associated
with an increased risk (relative risk = 2.29) of developing plasma cell
dyscrasias [46]. Several researchers even reported cases of DM-related
MM [47–48]. Similarly, a few case reports described PM associated
with MM [49–50]. Unlike the situation in DM, the diagnosis of PM
occurred either simultaneously or after the diagnosis of MM. Chronic
immune stimulation that occurs in PM/DM is thought to cause T-cell
and B-cell activation, thus leading to the development of certain hema-
tologic malignancies including MM [51].5.4. Sjogren's syndrome
There have been reports in literature linking Sjogren's syndrome
(SS) and MM [6,13]. SS is a chronic autoimmune disease featuring a
progressive lymphocytic proliferation and destruction of the salivary
and lacrimal glands causing xerostomia and xeropthalmia. An increased
risk of NHL and thyroid cancer has been reported in patients with SS
[52]. Several cohort studies found an increased risk of MM and MGUS
in patients with primary SS, while several reports described SS preced-
ing MM [53–55]. In addition, there has been an increased incidence of
free monoclonal light chains and proteins detected in serum and urine
in patients with SS, withmonoclonal IgG as themost frequent immuno-
globulin detected [56–58]. Another study by Tomi et al. [59] found an
increased risk of monoclonal gammopathy in patients with SS, where
a longer duration and higher severity of SS correlated with the highest
risk. Although exact mechanism remains unclear, chronic inﬂammation
as a potential trigger for the development of MM is hypothesized [53].
Patients with concurrent SS and MM demonstrated clinical improve-
ment of SS after treatment with thalidomide and dexamethasone
[60]. This suggests a possible causal relationship between the two
disorders.5.5. Ankylosing spondylitis
Ankylosing spondylitis (AS) is an inﬂammatory rheumatic disease
involving the axial skeleton. A retrospective cohort of over 4 million
United States (US) white and black male veterans followed for
27 years found a signiﬁcantly increased relative risk of 2.29 of develop-
ing MM and MGUS in subjects with AS [46]. Several reports describe
development of MM in patients with longstanding AS [61–66]. Among
those cases, one patient had IgA lambda and ﬁve patients had IgA
kappa multiple myeloma. In all reported cases the diagnosis of AS
preceded the diagnosis of MM. While the exact mechanism for this
association is unclear, persistent plasma cell stimulation and activation
in AS has been proposed as a potential trigger for IgA MM [61].5.6. Leukocytoclastic vasculitis
Leukocytoclastic vasculitis (LCV) represents a small vessel vasculitis
that may present as palpable purpura. Although data is limited on the
relationship between vaculitides and MM, several studies suggested
an association between the two. A case series by Bayer-Garner and
Smoller [67] evaluated eight patients with concomitant MM and LCV.
This study found that all patients had IgG myeloma associated with
LCV. In contrast, several case-reports described IgAmyeloma associated
with LCV [68–72]. Another report describes a patient who developed
MM, retinal vasculitis and temporal arteritis [73]. While the exact path-
ogenesis for the development of LCV in MM is unknown, some authors
postulated that overexpression of IL-6 genes in MMmay contribute to
the development of LCV [67].6. Autoimmune neurologic disorders in multiple myeloma
Several retrospective cohort studies have reported the presence of
autoimmune neurologic disorders including myasthenia gravis (MG)
and multiple sclerosis (MS) in patients with plasma cell dyscrasias,
includingMM(Table 3) [9,74–75]. One report describedMM that devel-
oped in a patient suffering fromMS for 26 years [76]. Similarly, a case of
Waldenstrom's macroglobulinemia was described in a patient suffering
fromMS for 39 years [77]. Conversely,MS and peripheral demyelinating
neuropathies have been described in patients with monoclonal
gammopathies [78]. These ﬁndings suggest a possible association
between monoclonal gammopathies and demyelinating neuropathies,
which is thought to be due to shared genetic susceptibility. Indeed,
one study demonstrated increased frequency of MS in relatives of
1317 MM patients [79].
Cases of coexistence of MG and MM in the literature are rare. In one
case report, MG preceded the development of MM by 20 years [80].
In addition, MG was described in a patient with extramedullary
plasmacytoma and in another patient with MM [81–82].
Table 3
Neurologic and other autoimmune disorders associated with multiple myeloma in the literature.
Disease Proposed mechanism Epidemiology Therapy References
MG MG usually precedes MM Very rare May improve with MM therapy [74,75,80–82]
MS Genetic susceptibility Unknown No change [74–76,78,79]
MGN Monoclonal immunoglobulin deposition Unknown May improve with MM therapy [85]
IBD Increased B-cell and plasma cell activation may lead to MM Unknown No change [87,88]
IBD: inﬂammatory bowel disease. MG: myasthenia gravis. MGN: membranous glomerulonephritis. MM: multiple myeloma. MS: multiple sclerosis.
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Published data have suggested that some agents used to treat auto-
immune disorders might confer an increased risk of myeloma. In partic-
ular, a case-control study found a 5-, 3-, and 6-fold increased risk of
developing multiple myeloma in women taking prednisone, insulin,
and goutmedications (e.g. sulphinpyrazone and colchicine), respectively
[1,9].
On the other hand, somemultiplemyeloma therapies can also lead to
the development of autoimmune conditions. In 2009, for the ﬁrst time,
Dasanu and Alexandrescu reported a case of lenalidomide-induced
aplastic anemia that resolved spontaneously after the discontinuation
of lenalidomide [83]. In 2014, a retrospective study by Montefusco
et al. [84] found a 4.3% absolute risk of autoimmune disorders in MM
patients treatedwith lenalidomide.Most autoimmune conditions devel-
oped within six months of starting therapy. These diseases included
AIHA, ITP, Evans syndrome, optic neuritis, autoimmune thyroiditis,
polymyositis, and cutaneous vasculitis. In that study, autologous stem
cell transplantation for multiple myeloma was also associated with a
statistically signiﬁcant increased risk of developing autoimmune
disorders.
8. Other autoimmune disorders in multiple myeloma
Renal abnormalities such as tubular light-chain deposition disease,
interstitial nephritis, primary amyloidosis and monoclonal deposition
disease are well-recognized in patients with MM [85]. However,
nephrotic syndrome is a rare presentation inMM.A case-series by Thachil
et al. [86] describes two MM patients who developed membranous
glomerulonephritis. Nephrotic syndrome resolved after the myeloma
therapy, suggesting an association between MM and membranous
glomerulonephritis. Monoclonal immunoglobulin deposition is thought
to play a role in the pathogenesis of nephrotic syndrome in MM [86].
A large, retrospective cohort study of patients with multiple myelo-
ma suggested that inﬂammatory bowel disease (IBD)may be associated
with the development of MM [9] (Table 3). Minami et al. described
instances of MM in patients with ulcerative colitis (UC) and Crohn's dis-
ease [87]. In both cases, MM developed during a long-term observation
of patients with IBD. There have been nine additional reported cases of
MMdeveloping in the setting of IBD [88]. In these cases, the diagnosis of
MM was made between 6–30 years after the diagnosis of IBD. While
anti-TNF therapies (i.e. inﬂiximab) could have played a role in the
development of MM, only 3 of 9 patients were treatedwith such agents.
This suggests that mechanisms involving increased B-cell activation
might be responsible for the development of MM in IBD [88].
9. MGUS and autoimmunity
MGUS is known to precede MM, and carries an average 1% annual
risk of progression to MM. Indeed, on a molecular level, MM is consis-
tently preceded by MGUS [89]. Nonetheless, most cases of MGUS
never progress to a full-blown MM. While the pathogenesis of MGUS
and MM is still not well-understood, there is evidence that immune
dysregulation and/or sustained immune stimulation may play a role in
the development of these two hematologic entities [90]. A recent
population-based study and a case-series showed clearly that severalimmune-mediated conditions were associated with a signiﬁcant risk
of developing MGUS [91,92].
A recent meta-analysis demonstrated that autoimmune conditions
were associated with a nearly 42% increase in risk of MGUS [9]. Similar
to the situation inMM, patients with pernicious anemia display a signif-
icantly increased risk of developing MGUS [9]. Furthermore, this study
found a non-signiﬁcant association between ankylosing spondylitis
and polymyositis/dermatomyositis with MGUS [9].
A study of United States veterans suggested that subjects with
autoimmune conditions where autoantibodies are detectable are at
increased risk of developing MGUS [46]. Furthermore, a recent
population-based study found that personal or family history of autoim-
mune disease increases the risk of developingMGUS [91]. In that study,
history of giant cell arteritis, polymyalgia rheumatica and rheumatoid
arthritis was associated with a signiﬁcantly increased risk of MGUS
[91]. Two additional case-series demonstrated an increased prevalence
of autoimmune axonal or peripheral demyelinating neuropathy in
patients with MGUS [93,94].
In a recent prospective study, 15% patients with MGUS were found
to have a preceding autoimmune disorder [95]. Sjogren's syndrome,
polymyositis and vitiligo have been reported to precede the develop-
ment of MGUS in three patients from Senegal [92]. Interestingly, their
monoclonal components stabilized after the treatment of their autoim-
mune conditions. Another case series reported four patients with
Sjogren's syndrome , Kikuchi disease, neuromyelitis optica and ankylos-
ing spondylitis, respectively, who developed MGUS either coincidently
or up to 10 years after the diagnosis of the autoimmune condition [90].
Several studies have found that inﬂammatory/infectious conditions
such as pneumonia, sepsis, meningitis and osteoarthritis increase the
risk of developing MGUS and in some cases - of MM [46,91]. This
suggests that an overwhelming inﬂammatory process can trigger the
development of MGUS and myeloma. It had been proposed that
infections can lead to a clonal proliferation by serving as a trigger for
certain genetic translocations [96].
Taken together, these ﬁndings suggest that autoimmune diseases
and inﬂammatory conditions may increase the risk of developing
MGUS. As a result, chronic antigen stimulationmay trigger the develop-
ment of a plasma cell dyscrasia. Alternatively, theremight be a common
genetic or environmental susceptibility for developing both an autoim-
mune disease and a MGUS.10. Discussion and conclusions
Patients with MM appear to be at increased risk for various autoim-
mune conditions. Nonetheless, information available in the literature on
autoimmune conditions in patients with MM/MGUS consists largely of
retrospective analyses of case series or isolated reports. This might
limit the accuracy of our analysis. Some conclusions of our review
might render an overestimation of the association between autoim-
mune conditions and MM due to the retrospective nature of most
studies on this topic in the published literature. Presence of publication
bias is another concern, reﬂecting the fact that studies reportingpositive
associations are more likely to be published than studies reporting
negative associations. Finally, some associations between instances of
autoimmunity and MM/MGUS could represent a mere coincidence.
17A. Shimanovsky et al. / BBA Clinical 6 (2016) 12–18Etiopathogenesis of autoimmune conditions andMMappearsmulti-
factorial and complex. Furthermore, insights from pathophysiology
could explain the risk for both diseases. In most cases, development of
an autoimmune condition precedes the development of MM. This
echoes the hypothesis made by Rudolf Virchow who, in 1863,
stated that the origin of cancer at different sites was due to chronic
inﬂammation. Consequently, MM/MGUS could develop due to chronic
inﬂammation in the setting of autoimmune disorders. Chronic antigenic
stimulation of B-lymphocytes present in autoimmune disorders might
eventually lead to clonal proliferation, and ultimately to MM. In
addition, defective immune surveillance in autoimmunity may lead to
pre-selection of speciﬁc B-cell clones, thus triggering development of
MM. Moreover, some studies suggested shared genetic susceptibility
for both conditions.
Many autoimmune diseases could be primary, andmay play a role in
the pathogenesis of MGUS/MM. Conversely, autoimmune conditions
may develop after the diagnosis of MGUS/MM has been made. Future
studies are needed to better understand the relationship between MM
and autoimmune disorders. The autoimmune conditions can pose
signiﬁcant clinical problems for the MM patients and health care
providers; therefore, a catalogue of this information is important to
raise awareness and improve timely diagnosis and management.
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